Envoy Medical, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COCH research report →
Range $2 – $2
Price Chart
About the company
Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants.
- CEO
- Brent T. Lucas
- IPO
- 2021
- Employees
- 43
- HQ
- White Bear Lake, MN, US
Get TickerSpark's AI analysis on COCH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $51.89M
- P/E
- -1.84
- PEG
- -0.01
- P/S
- 230.32
- P/B
- -468.22
- EV/EBITDA
- -2.00
- Div Yield
- 0.00%
- Gross Margin
- -352.81%
- Op Margin
- -10151.52%
- Net Margin
- -9026.41%
- ROE
- -14973.79%
- ROIC
- -462.25%
Latest fiscal year · YoY change
- Revenue
- $241.00K+7.1%
- Gross Profit
- $-633,000-22.4%
- Op Income
- $-22,270,000
- Net Income
- $-23,756,000-14.2%
- EPS
- $-12.30+17.4%
- OCF Growth
- -1.4%
- FCF Growth
- +2.9%
- 52W High
- $9.54
- 52W Low
- $3.63
- 50D MA
- $6.77
- 200D MA
- $6.89
- Beta
- 2.02
- RSI (14)
- 48
- Avg Volume
- 16.43K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Envoy Medical reported a smaller Q3 loss and said its fully enrolled pivotal Acclaim cochlear implant study remains on track for final data collection in 2Q27 and potential FDA action by late 2027 or early 2028.· November 5, 2026
- Q3 net revenue was $66 thousand, up from $42 thousand a year ago, while net loss attributable to common stockholders improved to $5.2 million, or $0.50 per share, from $7.7 million, or $3.55 per share.
- R&D rose to $3.1 million from $2.7 million as the company expanded its pivotal trial into Stage 2; sales and marketing fell to $157 thousand from $405 thousand.
- The pivotal Acclaim FCI study is fully enrolled, all 56 participants have passed 6-month follow-up, and management expects data collection to finish by April/2Q27.
- The company submitted its first PMA module on 6/30/2026 and its second module on 10/12/2026, with the remaining two modules targeted for submission by the end of 2Q27.
- Management said cash was about $14.6 million at 9/30/2026 and emphasized disciplined capital allocation while preparing for commercialization.
For Q3 2026, Envoy Medical reported net revenue of $66 thousand versus $42 thousand in Q3 2025. Cost of goods sold was $244 thousand versus $203 thousand. R&D expense was $3.1 million versus $2.7 million, sales and marketing was $157 thousand versus $405 thousand, and G&A was $2.1 million versus $2.0 million. Net loss attributable to common stockholders was $5.2 million, or $0.50 per share, compared with $7.7 million, or $3.55 per share, a year ago. Cash was approximately $14.6 million at 9/30/2026. Forward-looking, management said the pivotal trial is fully enrolled, data collection is expected to be complete in 2Q27, the remaining two PMA modules including the final clinical module are expected by the end of 2Q27, and an FDA decision could come by the end of 2027 or in the first half of 2028.
Brent Lucas framed Envoy as a long-duration story centered on a fully implanted cochlear implant that avoids head-worn externals, magnets, and external microphones. He said the company believes patients want a fully implanted option and that the market could expand meaningfully if the product is approved. His tone was confident and upbeat, with repeated emphasis on differentiation, regulatory progress, and readiness for commercialization.
Robert Potashnick focused on the quarter’s spending mix and balance sheet. He said revenue from Esteem implants and battery replacements was $66 thousand, R&D was $3.1 million mainly because of Stage 2 trial expansion, sales and marketing declined to $157 thousand, G&A was $2.1 million, and the quarterly loss was $5.2 million or $0.50 per share. He also noted cash of about $14.6 million as of 9/30/2026 and said the company remains focused on disciplined capital allocation as it advances the pivotal study and PMA submission.
Analyst questions centered on commercial readiness, manufacturing scale-up, FDA feedback on the modular PMA, trial signal consistency, and the competitive landscape. Management said it plans to grow from about 50 employees to roughly 70-75 over the next 12-18 months, hire a commercial leader, and expand manufacturing capacity toward 10,000-15,000 units annually over time. On the FDA and trial, Lucas said feedback so far has validated the modular PMA approach and that Stage 2 appears on a similar efficacy track to Stage 1, while also noting there is a learning curve for clinicians using the middle-ear sensor. He added that all three companies in fully implanted cochlear implants are drawing more attention, but Envoy believes its middle-ear sensor, lack of a magnet, and chest battery remain differentiators.
The company is still advancing a potentially differentiated product with a fully enrolled pivotal study and two PMA modules already submitted. Management sounded confident that demand could be meaningful if approved, citing an underpenetrated cochlear implant market and saying the company could eventually scale without needing outsized sales and marketing spending.
Envoy remains pre-revenue in a commercial sense, with only $66 thousand of quarterly revenue and a $5.2 million loss in the quarter. The company still has to complete follow-up, submit the final PMA modules, and wait for FDA review, while management acknowledged a learning curve for clinicians and patient-to-patient variability in programming and healing. Cash of $14.6 million suggests continued dependence on careful capital management as the timeline extends into 2027-2028.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 56.1%
- Shares Outstanding
- 7.74M
- Float Shares
- 4.34M
of shares held by institutions
33 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 7.68M | ▲ 28.68K |
| Bleichroeder LP | 6.25M | 0 |
| Vanguard Capital Management LLC | 880.21K | 0 |
| Dsg Capital Advisors, LLC | 625.00K | 0 |
| Geode Capital Management, LLC | 561.53K | ▲ 19.81K |
| Exoduspoint Capital Management, LP | 494.47K | ▲ 312.12K |
| Vanguard Group Inc | 347.30K | ▲ 8.19K |
| Vanguard Fiduciary Trust Co | 296.68K | 0 |
| Northwestern Mutual Wealth Management Co | 250.00K | ▲ 250.00K |
| Cibc Bancorp Usa Inc. | 174.04K | ▲ 96.15K |
| Northern Trust Corp | 109.47K | 0 |
| Mariner, LLC | 100.00K | ▲ 100.00K |
Held by 21 ETFs
Biggest fund positions in COCH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 24, 26 | Potashnick Robert | other | 250,000 |
| Jun 19, 26 | Lucas Brent T. | other | 1,000,000 |
| Jun 19, 26 | Lucas Brent T. | other | 1,000,000 |
| May 29, 26 | Lucas Brent T. | other | 32,856 |
| Apr 15, 26 | McKhann Chas | other | 100,000 |
| Apr 15, 26 | McKhann Chas | other | 0 |
| Feb 12, 26 | Patel Mona Chetan | buy | 312,500 |
| Feb 12, 26 | Patel Mona Chetan | buy | 312,500 |
| Feb 12, 26 | Patel Mona Chetan | buy | 187,500 |
| Feb 12, 26 | Potashnick Robert | buy | 212,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our COCH coverage
Recent articles, reports, and earnings notes.
No research on COCH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate COCH report →Envoy Medical Expands Intellectual Property Portfolio to 99 Patents with New U.S. and Hong Kong Patent Grants
newsfilecorp.com · Nov 17
Envoy Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
newsfilecorp.com · Nov 10
Envoy Medical, Inc. (COCH) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 5
Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress
feeds.newsfilecorp.com · Nov 5
Envoy Medical Updates Third Quarter 2026 Earnings Call Time to 8:00 A.M. ET on Thursday, November 5th
newsfilecorp.com · Oct 28
Envoy Medical to Report Third Quarter 2026 Financial Results on Thursday, November 5th
newsfilecorp.com · Oct 27
Envoy Medical Announces Reverse Stock Split
newsfilecorp.com · Oct 22
Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device Design
newsfilecorp.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.